Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+ T-Cell Response in Allogeneic Stem Cell Transplant Recipients by Clari, María Ángeles et al.
Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for
Detection and Estimation of the Magnitude and Functionality of the
CMV-Specific Gamma Interferon-Producing CD8 T-Cell Response in
Allogeneic Stem Cell Transplant Recipients
María Ángeles Clari,a Beatriz Muñoz-Cobo,a Carlos Solano,b,c Isabel Benet,b,c Elisa Costa,a María José Remigia,b Dayana Bravo,a
Paula Amat,b and David Navarroa,d
Microbiology Service, Hospital Clínico Universitario, Valencia, Spaina; Hematology and Medical Oncology Service, Hospital Clínico Universitario, Valencia, Spainb;
Department of Medicine, School of Medicine, University of Valencia, Valencia, Spainc; and Department of Microbiology, School of Medicine, University of Valencia,
Valencia, Spaind
The performance of the QuantiFERON-cytomegalovirus (CMV) assay was compared to that of a flow cytometry intracellular
cytokine staining (ICS) method for the detection of CMV-specific gamma interferon (IFN-)-producing CD8 T-cell responses
in allogeneic stem cell transplant (allo-SCT) recipients and for estimations of their magnitude and functionality. A total of 90
whole-blood specimens from 23 allo-SCT recipients was analyzed by both methods. Overall, the percentage of specimens that
yielded concordant results by both methods was 68.8% ( 0.691; 95% confidence interval [CI], 0.548 to 0.835), and the sensi-
tivity of the QuantiFERON-CMV assay for the detection of positive IFN- T-cell responses (>0.2 IU/ml), taking the ICSmethod
as the reference, was 76.3%. The magnitude of IFN--producing CD8 T-cell responses to CMV-specific peptides measured with
the QuantiFERON-CMV assay correlated significantly ( 0.695; P<0.001) with that of the total IFN--producing CD8 T
cells and dual-functional (IFN-/tumor necrosis factor alpha [TNF-] [ 0.652; P<0.001] and IFN-/CD107a [ 0.690;
P<0.001]) and trifunctional (IFN-/TNF-/CD107a [ 0.679; P>0.001]) CMV-specific CD8 T-cell responses, as quan-
titated by ICS. In summary, the data indicated that the QuantiFERON-CMV assay is less sensitive than the ICSmethod for the
detection of CMV-specific IFN--producing CD8 T-cell responses in the allo-SCT setting. Nevertheless, it allowed the estima-
tion of the total and polyfunctional CMV-specific IFN--producing CD8 T-cell responses in specimens that tested positive by
both methods.
The assessment of themagnitude and the functionality of T-cellimmunity against cytomegalovirus (CMV) is emerging as a
clinically useful tool for the therapeutic management of CMV
infection in the allogeneic stem cell transplantation (allo-SCT)
setting (7, 13). The monitoring of CMV-specific CD8 or CD4
T-cell responses may allow for the optimization of preemptive
antiviral therapy regimens on an individual basis and the identi-
fication of patients whomay benefit fromprophylactic antiviral or
adoptive T-cell transfer therapeutic strategies (1, 7, 13). In recent
years, several methods have been developed for the ex vivo quan-
titation and functional characterization of T-cell responses,
among which flow cytometry for surface immunophenotyping
and intracellular cytokine staining (ICS) are currently considered
the “gold standard” (13). The QuantiFERON-CMV assay (Celles-
tis Ltd.,Melbourne, Australia) is a commercially available test that
allows the inference of the size of the CMV-specific T-cell re-
sponse by quantitating the level of gamma interferon (IFN-),
produced mostly by CMV-specific CD8 T cells, upon the stim-
ulation of whole blood with a number of immunogenic peptides
mapped within IE-1, IE-2, pp65, pp50, and gB and restricted by
several widespread HLA-I haplotypes (17). The performance of
the QuantiFERON-CMV assay has been assessed mostly in the
solid-organ transplant (SOT) setting (see reference 4 for a review).
Recently reported data, although preliminary, lend support to the
suitability of theQuantiFERON-CMVassay for themonitoring of
the CMV-specific IFN--producing CD8 T-cell responses in
allo-SCT recipients (2). Nevertheless, it is largely unknown how
this method compares to ICS assays for such a purpose. In previ-
ous studies, we reported the development and clinical utility of an
ICS assay for the quantitation of CMV-specific IFN--producing
CD8 and CD4 T cells (11, 12, 14–16). The assay was found to
reliably predict protection from the development of CMV
DNAemia in allo-SCT recipients, and it was recently used in the
setting of a novel strategy for the guidance of preemptive antiviral
therapy based on combined virological and immunological mon-
itoring (12). In the current study, we compared the performance
of the QuantiFERON-CMV assay with that of our ICSmethod for
the detection and quantitation of CMV-specific IFN--producing
CD8 T-cell responses in allo-SCT recipients.
MATERIALS AND METHODS
Patients and specimens. A total of 90 whole-blood samples, obtained
from 23 nonconsecutive patients (median age, 53 years [range, 20 to 71
years]; 16males and 7 females) who underwent peripheral blood (n 20)
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or umbilical cord blood (n 3) allo-SCT at the Hospital Clínico Univer-
sitario of Valencia, Spain, between February 2010 and June 2011, was
analyzed in this study. The underlying diseases of the patients were acute
myeloid leukemia (n 10), non-Hodgkin’s lymphoma (n 7), chronic
lymphocytic leukemia (n 2), multiple myeloma (n 2), or myelodys-
plastic syndrome (n  1). The types of transplant were related/matched
(n 10), unrelated/matched (n 9), unrelated/mismatched (n 3), and
related/mismatched (n  1). The conditioning regimen was nonmyelo-
ablative (n 17) or myeloablative (n 6), and the paired CMV serosta-
tuses of the donors (D) and recipients (R) were D/R (n 9), D/R
(n 9), D/R (n 2), and D/R (n 3). The study was approved by
the Ethics Committees. All patients gave their informed consent to par-
ticipate in the study.
CMV serology. The CMV serological testing of the donors and recip-
ients was performed by use of the DiaSorin Liaison CMV IgG assay (Dia-
Sorin, Saluggia, Italy) according to the recommendations of themanufac-
turer.
CMV plasma DNAemia quantitation. The CMV DNA load in the
plasma was quantitated by real-time PCR (Abbott CMV PCR kit; pro-
duced by Qiagen GmbH, Hilde, Germany, for Abbott Diagnostics, Des
Plaines, IL). The PCRs were performed by using the m2000RT system
(AbbottMolecular, IL), as previously described (3). The DNA extractions
were performed by using 500 l of plasma on an m24 SP instrument
(Abbott Diagnostics, IL).
Enumeration of CMV-specific IFN--producing CD8 T cells. The
quantitation of the total numbers of CMV-specific IFN--producing
CD8 T cells and selectively bifunctional (IFN-/tumor necrosis factor
alpha [TNF-] and IFN-/CD107a) and trifunctional (IFN-/TNF-/
CD107a)CMV-specific IFN--producingCD8T cells was performedby
ICS.Whole blood (0.5ml) was simultaneously stimulated with two sets of
15-mer overlapping peptides encompassing the sequence of the pp65 and
IE-1 CMV proteins (1 g/ml/peptide), obtained from JPT Peptide Tech-
nologies GmbH (Berlin, Germany), in the presence of 1 g/ml of co-
stimulatorymonoclonal antibodies (MAbs) to CD28 andCD49d, an anti-
CD107a MAb coupled with allophycocyanin (APC), brefeldin (5 g/ml),
and monensin (1 M) for 6 h at 37°C. The cells were washed in phos-
phate-buffered saline (PBS)–2% fetal calf serum (FCS), lysed in BD FACS
lysis solution, stained with surface markers (anti-CD8-peridinin chloro-
phyll protein [PerCP]–Cy5-5 and anti-CD3-APC-Cy7), permeabilized
(BD FACS permeabilizing solution 2), washed, and finally stained for
intracellular cytokines (anti-IFN-–fluorescein isothiocyanate [FITC]
and anti-TNF-–phycoerythrin [PE]). All antibodies and solutions were
purchased fromBectonDickinson (San Jose, CA). The cells were stored at
4°C in PBS–1% formaldehyde, acquired within 4 h with a BD FCSCantoII
flow cytometer (BD Biosciences Immunocytometry Systems, San Jose,
CA), and analyzed with the software program Infinicyt (Cytognos, Sala-
manca, Spain). The negative controls (absence of peptide stimulation)
were processed in parallel for all experiments. The total number of each
CD8 T-cell subpopulation was calculated by multiplying the corre-
sponding percentage of CMV-specific T cells (after background subtrac-
tion) by the absolute number of CD8 T cells. Specific responses were
considered those that were 0.1% for each population. CMV-specific
IFN--producing CD8 T cells were enumerated in parallel by using the
BD Fastimmune kit (BD-Becton Dickinson and Company Biosciences,
San Jose, CA) as previously described (11, 12, 14–16) but employing the
BDFCSCantoII flow cytometer and the software program Infinicyt for the
analyses. The levels of IFN--producing CD8 T cells (total number)
measured by the two above-described procedures were comparable (data
not shown).
QuantiFERON-CMV assay. The QuantiFERON-CMV assay (Celles-
tis Ltd., Melbourne, Australia) was performed according to the manufac-
turer’s instructions. Briefly, 1-ml aliquots of heparinized whole blood
were collected into three QuantiFERON-CMV collection tubes, one con-
taining a number of CMV immunogenic peptides (CMV antigen), an-
other with no peptides (nil control), and the other containing a polyclonal
stimulating antigen (phytohemagglutinin) (mitogen control). The tubes
were shaken vigorously for 5 s and then incubated for 18 to 24 h at 37°C.
The supernatants were then harvested, and the levels of IFN- were mea-
sured by an enzyme-linked immunosorbent assay (ELISA). A standard
curve was generated for each run. The results of the assay were interpreted
according to the criteria established by the manufacturer: (i) nonreactive
at0.2 IU/ml (CMVminus nil) and0.5 IU/ml (mitogenminus nil), (ii)
reactive at0.2 IU/ml (CMVminus nil) and any value of mitogenminus
nil, and (iii) indeterminate at 0.2 IU/ml (CMV minus nil) and 0.5
IU/ml (mitogen minus nil). According to the manufacturer, indetermi-
nate results are not interpretable.
Statistical analysis. The data were analyzed with the aid of the statis-
tical package SPSS, version 17.0 (SPSS, North Chicago, IL). Differences
between the medians were compared by using the Mann-Whitney U test.
Spearman’s rank testwas used to analyze correlations between continuous
variables. Two-sided exact P values are reported. A P value of0.05 was
considered statistically significant.
RESULTS
A total of 90 blood samples from 23 allo-SCT recipients was ana-
lyzed by ICS and by the QuantiFERON-CMV assay. The data are
summarized in Table 1. Fifty-five samples (61.1%) from 17 pa-
tients hadCMV-specific IFN--producingCD8T-cell responses
detectable by ICS; of these, 42 samples (76.3%) from 13 patients
were reactive (0.2 IU/ml), and 13 samples (from 4 patients)
yielded negative (n 10) or indeterminate (n 3) results by the
QuantiFERON-CMV assay. As shown in Fig. 1, specimens that
tested positive by the QuantiFERON-CMV assay displayed signif-
icantly higher (P 0.001) numbers of CMV-specific IFN--pro-
ducing CD8 T cells, as measured by ICS, than those that tested
negative or indeterminate. As shown in Table 1, 35 specimens
from six patients lacked detectable CMV-specific IFN--produc-
ing CD8 T-cell responses, as determined by ICS. Of these, only
one sample yielded a positive result by the QuantiFERON-CMV
assay (2.5 IU/ml). All patients (and/or their donors) with negative
results by the QuantiFERON-CMV assays throughout the study
period displayed at least one HLA-I specificity able to present one
of the immunogenic peptides included in the QuantiFERON-
CMV assay pool (data not shown). A large number of specimens
gave indeterminate results by theQuantiFERON-CMVassay (n
17; 18.8%); most of these samples (n  14) had no detectable
CMV-specific IFN--producing CD8 T-cell responses, as mea-
sured by ICS. Overall, the percentage of specimens that yielded
concordant results by both methods was 68.8% (	  0.691; 95%
confidence interval [CI], 0.548 to 0.835), and the sensitivity of the
QuantiFERON-CMV assay for the detection of positive IFN-
T-cell responses, as determined by ICS, was 76.3%. Three speci-
mens that tested positive by the ICS assay displayed IFN- levels
within the range of 0.1 to 0.2 IU/ml in the QuantiFERON-
CMV assay. Thus, a decrease of the cutoff level for a positive result
to0.1 IU/ml resulted in a slight increase in the sensitivity of the
TABLE 1 Detection of cytomegalovirus-specific IFN--producing
CD8 T cells by ICS and the QuantiFERON-CMV assay in whole-blood
specimens from allogeneic stem cell transplant recipients
Result of ICS method
(no. of specimens)
No. of specimens with QuantiFERON-CMV
assay result of:
Positive Negative Indeterminate
Positive (55) 42 10 3
Negative (35) 1 20 14
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QuantiFERON-CMV assay (81.8%). Of note was the fact that 15
out of the 42 specimens that tested positive by theQuantiFERON-
CMV assay gave optical density values above the upper limit of
quantification of the assay and thus had to be further diluted in
order to determine precisely the levels of IFN-.
We next assessed to what extent the QuantiFERON-CMV as-
say allowed size and functional diversity estimations of CMV-
specific IFN--producing CD8 T-cell responses, as determined
by ICS. For this, we performed an analysis of the correlation of the
levels of IFN-measured by the QuantiFERON-CMV assay with
the number of different functional populations of IFN--produc-
ing CD8 T cells quantitated by the ICS assay for 42 specimens
that showed detectable responses by both methods. Note that
20 out of these 42 specimens were obtained during episodes
of nontreated (n  11 from 3 patients) or ganciclovir-treated
(n  9 from 2 patients) CMV plasma DNAemia. In addition,
the remaining 22 specimens were obtained from eight patients
who had a prior episode of CMV DNAemia. As shown in Fig. 2,
the magnitude of the IFN- responses to the CMV-specific peptides
measured with the QuantiFERON-CMV assay was significantly cor-
related (
0.695;P0.0001)with thatquantitatedby ICS for the
total IFN--producing CD8 T cells. Furthermore, the IFN- levels
determinedby theQuantiFERON-CMVassaywere also significantly
correlated with the number of dual-functional (
  0.652 and P
0.001 for IFN-/TNF-; 
  0.690 and P  0.0001 IFN-/
CD107a) and trifunctional (
 0.679 and P0.0001 for IFN-/
TNF-/CD107a) CMV-specific CD8 T cells.
DISCUSSION
TheQuantiFERON-CMVassay is the only commercially available
method for the measurement of CMV-specific IFN--producing
CD8 T-cell responses. This assay was previously evaluated with
SOT and allo-SCT recipients (2, 4, 5, 8, 10, 17, 18). Preliminary
data supported the clinical utility of this method for the assess-
ment of the risk of late-onset CMV end-organ disease in SOT
recipients (5) and for the prediction of the occurrence of CMV
DNAemia in allo-SCT patients (2). Nevertheless, information on
how the QuantiFERON-CMV assay correlates with ICS methods
for estimations of themagnitude and assessments of the function-
ality of CMV-specific CD8 T-cell responses in transplant recip-
ients is still scarce. In the current study, we compared the perfor-
mance of the QuantiFERON-CMV assay with that of an ICS
method developed by our group that has been proven to be clin-
ically useful in the management of active CMV infection in the
allo-SCT setting (11, 12, 14–16). Overall, we found both methods
to yield concordant qualitative results for around 70% of speci-
mens. This findingwas not entirely unexpected, as 18 out of the 21
peptides included in the CMV tube of the QuantiFERON-CMV
assay map within pp65 (n  15) and IE-1 (n  3). When the
results of the QuantiFERON-CMV assay were interpreted as indi-
cated by the manufacturers (positive responses if IFN- levels
were0.2 IU/ml), the sensitivity of the assay, considering the ICS
method as the reference assay, was 76.37%. The sensitivity of the
assay slightly improved (81.8%) when the cutoff threshold for
FIG 1 Number of cytomegalovirus pp65/IE-1-specific IFN--producing CD8 T cells (total) enumerated by flow cytometry for intracellular cytokine staining
(ICS) of specimens that tested positive, negative, or intermediate by theQuantiFERON-CMVassay. The data are given as log10 values; each dot represents a single
measurement, and the bars represent median values.
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positive IFN- responses was lowered to 0.1 IU/ml, as previously
suggested (5). All patients (and/or their donors) who tested negative
by the QuantiFERON-CMV assay throughout the study period dis-
played at least one HLA-I variant included among the specificities
covered by the test. The specificity of theQuantiFERON-CMV assay
approached 100%. In fact, there was only one specimen that gave a
positive result by theQuantiFERON-CMVassay (2.5 IU/ml)but that
tested negative by the ICSmethod; this could have been a false-posi-
tive result, since a follow-up specimen obtained 3 days later from the
same patient tested negative by both assays. The QuantiFERON-
CMVassay gave a large number of indeterminate results. This obser-
vation is in keeping with previously reported data (2). Most of the
specimens that yielded indeterminate results (14 out of 17) and those
that tested negative had undetectable CMV-specific IFN--produc-
ing CD8 T-cell responses, as measured by ICS.
The levels of IFN-measured by the QuantiFERON-CMV as-
say were found to correlate significantly with the total number of
CMV-specific IFN--producing CD8 T cells quantitated by the
ICS assay. This observation is in accordancewith the data reported
in a recent study in which the QuantiFERON-CMV assay was
compared to an ICS method using a library of CMV peptides
mapped within pp65 as the stimulating antigen (2).
Recent data seem to favor the idea that polyfunctional rather
than monofunctional CMV-specific CD8 T cells, in particular
those with the ability to produce cytokines with antiviral proper-
ties, such as IFN- and TNF-, and to simultaneously display
cytotoxic activity (cells expressing CD107a), are crucial for pro-
tection from and the resolution of episodes of active CMV infec-
tion in the allo-SCT setting (6, 10, 19). The QuantiFERON-CMV
assay cannot distinguish between different functional CD8 T-
cell populations producing IFN- in response to CMV replica-
tion. In this context, wewere interested to assess towhat extent the
QuantiFERON-CMV assay could allow the estimation of levels of
CMV-specific polyfunctional IFN--producing CD8T cells.We
found that IFN- levels determined by the QuantiFERON-CMV
assay significantly correlated with the number of CMV-specific
dual-functional (IFN-/TNF- and IFN-/CD107a) and trifunc-
tional (IFN-/TNF-/CD107a) CD8 T cells. It should be
stressed that the above-described correlations were observed in a
very precise virological setting, i.e., in patients with an ongoing
FIG 2 Correlation between the number (log10) of pp65/IE-1-specific IFN--producing CD8
 T cells enumerated by flow cytometry for intracellular cytokine
staining (ICS) and IFN- levels (log10) measured by the QuantiFERON-CMV assay. The data for 42 whole-blood specimens (from 13 allogeneic stem cell
transplant recipients) that tested positive by both methods are depicted. (A) Total number of IFN--producing CD8 T cells; (B) dual-IFN-/TNF- CD8 T
cells; (C) dual-IFN-/CD107a CD8 T cells; (D) trifunctional (IFN-/TNF-/CD107a) CD8 T cells.
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episode of active CMV infection or in patients who had recently
resolved an episode of CMV DNAemia. In this context, we ob-
served that the expansion and contraction ofmonofunctional and
polyfunctional CMV-specific IFN--producing CD8 T-cell re-
sponses elicited by CMV replication followed different kinetic
patterns and also showed wide variations on an individual basis
(9). It is thus likely that the ability of the QuantiFERON-CMV
assay to accurately estimate the size of CMV-specific polyfunc-
tional IFN--producing CD8 T-cell responses may ultimately
depend on the past and current status of CMV replication. The
current study has two main limitations: first, both assays are not
entirely comparable, as they are of distinct natures and, most im-
portantly, employ different stimulating antigens (Table 2), and
second, the ICS method taken as the reference standard for the
measurement of CMV-specific CD8 T-cell responses in the cur-
rent study lacked extensive interlaboratory validation. Despite
these limitations, we are convinced that studies to compare the
performance of the QuantiFERON-CMV assay with that of ICS
methods with proven reliability to assess and quantitate CMV-
specific IFN--producing CD8 T-cell responses conferring pro-
tection against CMV infection are of major clinical interest.
Table 2 summarizes the characteristics, advantages, and limi-
tations of the QuantiFERON-CMV assay and the ICS method
developed by our group. In summary, the data presented here
indicated that the QuantiFERON-CMV assay, although less sen-
sitive than our ICS method, allowed the estimation of total and
polyfunctional CMV-specific IFN--producing CD8 T-cell re-
sponses in specimens that tested positive by both methods. We
wonder whether the use of overlapping pp65 and IE-1 peptide
pools in theQuantiFERON-CMV assay instead of amix of immu-
nogenic CMV peptides would increase the sensitivity of the
method. Further studies should be undertaken to confirm our
observations and, most importantly, to assess the clinical utility of
the QuantiFERON-CMV assay in this setting. In this context, it
seems to be essential to establish threshold levels of IFN- associ-
ated with protection from or the resolution of episodes of active
CMV infection and CMV end-organ disease.
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